Page URL:

Gene therapy as a treatment for HIV patients

21 June 2010
Appeared in BioNews 563

A human RNA (ribonucleic acid)-based gene therapy trial to combat HIV (human immunodeficiency virus) has passed the first safety test.

US researchers modified human blood stem cells to make them resistant to the virus. The cells were then transplanted into four AIDS (acquired immune deficiency syndrome) patients and survived for up to two years without adverse effects.

The trial was based on an existing therapy for AIDS patients, which involves the transplantation of a patients' own previously saved blood stem cells back into their bloodstream in an attempt to prevent the development of lymphoma, a type of blood cancer. This latest trial transplanted blood stem cells engineered to be HIV-resistant alongside the patient's normal blood stem cells.

The engineered blood cells were manipulated in three ways, each via RNA-based gene therapy, to make them HIV-resistant. First, the cells expressed an RNA enzyme that prevented the production of the protein CCR5. HIV exploits the presence of CCR5 on the surface of immune cells to gain entry. 'We know from a lot of populations that this is a great target - it can down-regulate (HIV levels) by 90 per cent', said Professor John Rossi of the Beckman Research Institute, California, who was involved in the trial.

The cells were also manipulated to express two types of RNA that both disrupt, in different ways, the HIV viral protein tat, which is essential for its replication. The transplanted, modified cells were shown to survive for between 18 and 24 months in three of the four patients involved in the study.

'It's a small study, but it's a step in the right direction. The most promising thing is that it shows you can modify stem cells in a way that makes them [HIV-] resistant, and the progeny of those cells would still be resistant to HIV and would still be functional', said Associate Professor Pablo Tebas, a HIV researcher at the University of Pennsylvania, who was not involved in the study.

'What we really want to do now is increase the percentage of gene-modified cells in the patient', said Professor Rossi. Professor Rossi and colleagues hope to achieve this goal in collaboration with the Australian biotechnology company Benitech.

The research was published in Science Translational Medicine this month.

Gene Therapy for HIV Inches Forward
Business Week |  16 June 2010
Triple-punch gene therapy for AIDS patients
The Times of India |  17 June 2010
Triple-punch gene therapy targets HIV
Nature |  16 June 2010
8 May 2012 - by Helen Brooks 
HIV patients treated over a decade ago with genetically modified immune cells have suffered no serious side effects from the treatment. Although the cells may not have been successful in targeting and killing HIV-infected cells, the results are promising as they bolster the safety credentials of gene therapy for clinical use...
5 December 2011 - by Dr Tamara Hirsch 
US scientists have induced long-lasting HIV protection in mice from a single injection. Their study, published in the journal Nature, uses gene therapy to stimulate production of antibodies against the virus...
26 September 2011 - by Dr Louisa Petchey 
The success of a new gene therapy trial represents a significant step towards a 'functional cure' for HIV, US researchers announced this week. By mimicking the effects of a naturally occurring gene mutation that makes an individual resistant to infection, this therapy aims to reduce or eliminate the dependency of HIV patients on antiretroviral drugs....
4 July 2011 - by Mehmet Fidanboylu 
New research has revealed that a group of generic anti-HIV drugs may be linked to premature ageing. The study, which was carried out by UK scientists at the Institute of Genetic Medicine at Newcastle University, could explain why people treated with this class of drugs sometimes show signs of age-related conditions, such as heart disease and dementia....
7 March 2011 - by Dr Lux Fatimathas 
American researchers have successfully created immune cells resistant to HIV. T cells, which are the main target of HIV, were isolated from six HIV positive patients and genetically manipulated to confer resistance. The cells were injected back into the same patients and were able to survive and multiply...
23 February 2009 - by Ben Jones 
A phase 2 trial for a radical new, 'one shot' treatment for HIV has shown small but promising results. The research at the University of California, Los Angeles (UCLA), was published in the journal Nature Medicine and was described by the study leader Professor Mitsuyasu as a...
16 February 2009 - by Alison Cranage 
A case report published in the New England Journal of Medicine last week details a man who was HIV+ and, following a bone marrow transplant, now has no detectable signs of the virus. Human Immunodeficiency Virus (HIV) enters and destroys cells of the immune system, eventually causing...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.